Impact of treatment adherence on psoriasis severity: Insights from a multicenter cross-sectional study in Brazil

Background: Psoriasis is a chronic, non-contagious inflammatory skin disease with significant physical and quality-of-life impacts. In Brazil, its estimated incidence is 1.3%. Due to the complexity of the disease, effective management requires addressing multiple factors, with treatment adherence and persistence being critical challenges. Aim: To evaluate the correlation between psoriasis severity and treatment adherence and persistence among patients in Paraná, Brazil. Methods: This cross-sectional study included 133 psoriasis patients treated at the three primary specialized care centers in the state, between January 28, 2022, and December 9, 2022. Results: A negative correlation (−0.102, rs² = 1.04%) was observed between psoriasis severity and treatment adherence. Conversely, there was a positive correlation (0.2444, rs² = 5.97%) between psoriasis severity and treatment discontinuation history. Conclusion: Treatment interruptions were correlated with increased psoriasis severity, whereas higher adherence was associated with milder clinical manifestations. Relevance for patients: These findings underscore the critical role of consistent treatment adherence in managing psoriasis. Interruptions in treatment are linked to more severe forms of psoriasis, highlighting the detrimental effects of non-adherence. In contrast, patients who maintained high levels of adherence experienced less severe symptoms, emphasizing that consistent treatment is key to improved disease control. Strengthening patient-provider collaboration and adherence strategies can improve clinical outcomes and enhance quality of life.

- Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-212. doi: 10.1111/jdv.13854
- Romiti R, Amone M, Menter A, Miot HA. Prevalence of psoriasis in Brazil - a geographical survey. Int J Dermatol. 2017;56(8):e167-e168. doi: 10.1111/ijd.13604
- Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. doi: 10.1038/jid.2012.339
- Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590
- Romiti R, Carvalho AVE, Duarte GV. Consenso brasileiro de psoríase 2020 e algoritmo de tratamento da sociedade brasileira de dermatologia. An Brasil Dermatol (Portuguese). 2021;96(6):778-781. doi: 10.1016/j.abdp.2021.09.013
- Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301-1315. doi: 10.1016/S0140-6736(20)32549-6
- Campione E, Mazzilli S, Di Prete M, et al. The role of glutathione-S transferase in psoriasis and associated comorbidities and the effect of dimethyl fumarate in this pathway. Front Med (Lausanne). 2022;9:760852. doi: 10.3389/fmed.2022.760852
- Silva MF, Fortes MR, Miot LD, Marques SA. Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. An Bras Dermatol. 2013;88(5):760-763. doi: 10.1590/abd1806-4841.20132052
- Svoboda SA, Ghamrawi RI, Owusu DA, Feldman SR. Treatment goals in psoriasis: Which outcomes matter most? Am J Clin Dermatol. 2020;21(4):505-511. doi: 10.1007/s40257-020-00521-3
- Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: A systematic literature review. Patient Prefer Adherence. 2018;12:1483-1503. doi: 10.2147/PPA.S167508
- Stein Gold LF. Topical therapies for psoriasis: Improving management strategies and patient adherence. Semin Cutan Med Surg. 2016;35(2 Suppl 2):S36-S44; quiz S45. doi: 10.12788/j.sder.2016.006
- Alsubeeh NA, Alsharafi AA, Ahamed SS, Alajlan A. Treatment adherence among patients with five dermatological diseases and four treatment types - a cross-sectional study. Patient Prefer Adherence. 2019;13:2029-2038. doi: 10.2147/PPA.S230921
- Feldman SR, Cline A, Pona A, Kolli SS. Treatment Adherence in Dermatology. Berlin: Springer International Publishing; 2019.
- Wang Q, Luo Y, Lv C, et al. Nonadherence to treatment and patient-reported outcomes of psoriasis during the COVID-19 epidemic: A web-based survey. Patient Prefer Adherence. 2020;14:1403-1409. doi: 10.2147/PPA.S263843
- Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: Quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-943. doi: 10.1038/jid.2009.391
- Mucherino S, Rafaniello C, Serino M, et al. Drug utilization and measurement of medication adherence: A real world study of psoriasis in Italy. Pharmaceutics. 2023;15(12):2647. doi: 10.3390/pharmaceutics15122647
- Aoki KC, Wong S, Duong JQ, Feldman SR. Adherence to psoriasis therapies. Dermatol Clin. 2024;42(3):495-506. doi: 10.1016/j.det.2024.02.010
- Sá Justo KC, FIlho AB, Zonzini FHT, Dagostini JS, Faria AR, Tanaka AA, et al. Prevalence of Comorbidities in Patients with Psoriasis in Brazil: Preliminary Results of the Pharmacoepidemiological Study Pso.BRA. Int J Phys Med Rehabil. 2022;10(6):653.doi: 10.35248/2329-9096.22.10.653
- Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74. doi: 10.1097/00005650-198601000-00007
- Finlay AY, Khan GK. Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. doi: 10.1111/j.1365-2230.1994.tb01167.x
- Souza AF, Silva MRD, Santos JBD, Almeida AM, Acurcio FA, Alvares-Teodoro J. Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: A prospective observational study. Pharm Pract (Granada). 2021;19(2):2312. doi: 10.18549/PharmPract.2021.2.2312
- Martins GA, Arruda L, Mugnaini ASB. Validação de questionários de avaliação da qualidade de vida em pacientes de psoríase. An Brasil Dermatol. 2004;79:521-535.
- Avazeh Y, Rezaei S, Bastani P, Mehralian G. Health literacy and medication adherence in psoriasis patients: A survey in Iran. BMC Prim Care. 2022;23(1):113. doi: 10.1186/s12875-022-01719-6
- Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: A systematic literature review. J Eur Acad Dermatol Venereol. 2012;26 Suppl 3:61-67. doi: 10.1111/j.1468-3083.2012.04525.x
- Piragine E, Petri D, Martelli A, et al. Adherence and persistence to biological drugs for psoriasis: Systematic review with meta-analysis. J Clin Med. 2022;11(6):1506. doi: 10.3390/jcm11061506
- Aleshaki JS, Cardwell LA, Muse ME, Feldman SR. Adherence and resource use among psoriasis patients treated with biologics. Expert Rev Pharmacoecon Outcomes Res. 2018;18(6):609-617. doi: 10.1080/14737167.2018.1512408
- Bronckers I, Paller AS, West DP, et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol. 2020;156(4):384-392. doi: 10.1001/jamadermatol.2019.4835
- Dommasch ED, Lee MP, Joyce CJ, Garry EM, Gagne JJ. Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study. J Am Acad Dermatol. 2018;79(6):1061-1068. e1. doi: 10.1016/j.jaad.2018.06.053
- Yelamos O, Ros S, Puig L. Improving patient outcomes in psoriasis: Strategies to ensure treatment adherence. Psoriasis (Auckl). 2015;5:109-115. doi: 10.2147/PTT.S54070
- Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408-414. doi: 10.1001/archderm.140.4.408
- Bewley A, Burrage DM, Ersser SJ, Hansen M, Ward C. Identifying individual psychosocial and adherence support needs in patients with psoriasis: A multinational two-stage qualitative and quantitative study. J Eur Acad Dermatol Venereol. 2014;28(6):763-770. doi: 10.1111/jdv.12174
- Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25 Suppl 4:9-14. doi: 10.1111/j.1468-3083.2011.04060.x
- Ros S, Puig L, Carrascosa JM. Cumulative life course impairment: The imprint of psoriasis on the patient’s life. Actas Dermosifiliogr. 2014;105(2):128-134. doi: 10.1016/j.ad.2013.02.009
- Zhu B, Jing M, Yu Q, Ge X, Yuan F, Shi L. Treatments in psoriasis: From standard pharmacotherapy to nanotechnology therapy. Postepy Dermatol Alergol. 2022;39(3):460-471. doi: 10.5114/ada.2021.108445